Results 161 to 170 of about 321,312 (283)

Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients. [PDF]

Blood Cancer J
Cheema H, Shrestha A, Naqvi S, Muttineni S, Dronavalli S, Alrawabdeh J, Alzu'bi M, Schinke CD, Thanendrarajan S, Shaughnessy JD, Zhan F, Zangari M, van Rhee F, Hadidi SA.   +13 more
europepmc   +1 more source

Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: A prospective analysis in three large cohorts [PDF]

, 2018
Birmann, Brenda M, Buring, Julie E, Colditz, Graham A, Giovannucci, Edward, Lee, I-Min, Marinac, Catherine R, Rebbeck, Timothy R, Rosner, Bernard A, Townsend, Mary K   +8 more
core   +1 more source

Multiple Myeloma [PDF]

CA: A Cancer Journal for Clinicians, 1966
L F, Craver, D G, Miller
openaire   +2 more sources

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study analyzes the current landscape of personalized cancer vaccine clinical trials, highlighting trends in vaccine platforms, trial phases, and geographic distribution. Peptide and dendritic cell vaccines dominate early‐stage research, with promising immune responses observed in melanoma, glioblastoma, and urothelial cancer trials.
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials. [PDF]

J Natl Cancer Inst
Mainou M, Alsadhan M, Tsapa K, Visram A, Mian H, Popat R, Mai EK, Chakraborty R, Al Hadidi S, Mohan M, Szabo A, Van Oekelen O, Scheffer Cliff ER, Mohyuddin GR.   +13 more
europepmc   +1 more source

Posterior Reversible Encephalopathy Syndrome in a Patient with Multiple System Atrophy and Multiple Myeloma

Movement Disorders Clinical Practice, EarlyView.
Jackson Mitzner, Jenny Linnoila, Yanal Shaheen, Abby L. Olsen   +3 more
wiley   +1 more source

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
RVD with weekly bortezomib dosing in real‐world newly diagnosed transplant‐ineligible myeloma shows comparable efficacy and reduced toxicity compared to twice‐weekly trial protocols. ABSTRACT Background Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to ...
Samantha Kurniawan, Angela Hwang, Nicole Wong Doo, Tracy King, Christian Bryant, Jennifer Zhang, Kristina Whelan, Parisa Fani‐Molky, Giselle Kidson‐Gerber, Annmarie Bosco, Nada Hamad, Gurdeep Parmar, Fiona Kwok, Sam Lai, Silvia Ling, P. Joy Ho, Georgia McCaughan, Adam Bryant   +17 more
wiley   +1 more source

P837: MULTIPLE MYELOMA AND ADJACENT NK CELLS CAN EXPRESS THE MACHINERY TO INTEGRATE NEURONAL SIGNALS

HemaSphere, 2023
Ana Filipa Barahona, Roel Klein Wolterink, Antonio Galzerano, Emilie Carneiro, Joana Caetano, Bruna Velosa Ferreira, Ana Queirós, Cristina João   +7 more
doaj   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders. [PDF]

Blood Cancer J
Koo E, Albert S, Patrick B, Henia M, Rhiwi Y, McCudden C, Jimenez Zepeda V, Sandhu I, Chu M, Mian H, Visram A.   +10 more
europepmc   +1 more source